Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
BMI Calculator
Collaborate
About
EQOH
Careers
Contact Us
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Work with Us
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
BMI Calculator
Collaborate
About
EQOH
Careers
Contact Us
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Work with Us
EMJ Interactive
EMJ GOLD
CME
Join
FREE
Search type
Keyword
Author
Hematology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Interviews
Podcasts
Videos & Webinars
News
Infographics
Society updates
Submit A Paper
T-cell engager Shows Early Activity in Relapsed Multiple Myeloma
November 2026
An early MK-4002 trial identified a dose for further study in relapsed myeloma, alongside substantial toxicity.
Read more
10 Nov 2026
T-cell engager Shows Early Activity in Relapsed Multiple Myeloma
An early MK-4002 trial identified a dose for further study in relapsed myeloma, alongside substantial toxicity.
8 Nov 2026
Quizartinib Linked to Improved AML Survival Outcomes
Quizartinib was associated with improved 1-year overall survival and higher remission rates than midostaurin in adults with newly diagnosed FLT3-ITD-positive acute myeloid leukaemia.
7 Nov 2026
Maternal Haemoglobin Linked to Preterm Birth Risk
Maternal haemoglobin showed a U-shaped association with preterm birth, with risk thresholds varying throughout pregnancy and according to altitude.
3 Nov 2026
High-Risk Multiple Myeloma Linked to Earlier CAR-T Cell Failure
A multicentre study of 598 patients with relapsed or refractory multiple myeloma identified distinct high-risk features associated with early and delayed treatment failure following cilta-cel.
1 Nov 2026
CRISPR Screens Reveal New Genes Regulating Red Blood Cell Density
CRISPR screens identified 17 genes and 13 genomic regions linked to red blood cell density, providing new insights into how genetic variants influence red blood cell traits.
31 Oct 2026
SGLT2 Inhibitors Linked to Higher Haemoglobin and Haematocrit
A meta-analysis of 85 randomised clinical trials found that SGLT2 inhibitors were associated with modest increases in haemoglobin and haematocrit, alongside changes in erythropoietin and transferrin saturation.
27 Oct 2026
Pre-Closure Fibrinogen and Haemostasis in Spine Surgery
Pre-closure intraoperative fibrinogen has been associated with favourable early postoperative haemostasis in patients undergoing spinal deformity surgery.
13 Oct 2026
Hydroxyurea Does Not Increase Infection Risk in Sickle Cell Anaemia
Hydroxyurea was not associated with increased infection risk in children with sickle cell anaemia, with rates declining through treatment phases.
Loading posts...
1
2
3
…
56
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View